Mohamed Husseiny Elsayed | Immunotherapy | Innovative Research Award

Innovative Research Award

Mohamed Husseiny Elsayed
Beckman Research Institute of City of Hope

Mohamed Husseiny Elsayed
Affiliation Beckman Research Institute of City of Hope
Country United States
Scopus ID 8580986700
Documents 65
Citations 6,388
h-index 28
Subject Area Immunotherapy
Event Name International Top Pharmaceutical Awards
ORCID 0000-0002-3470-2858

The Innovative Research Award recognizes distinguished scientific achievements that contribute to the advancement of biomedical and pharmaceutical sciences. Mohamed Husseiny Elsayed has developed a research profile characterized by sustained contributions to immunotherapy, translational oncology, and therapeutic innovation. His scholarly output has supported the understanding of immune-mediated mechanisms and their application in clinical research environments.[1]

Abstract

This article presents an academic overview of Mohamed Husseiny Elsayed and his suitability for recognition through the Innovative Research Award. The assessment is based on publication activity, citation performance, research visibility, and contributions to immunotherapy-related investigations. Available scholarly indicators demonstrate consistent engagement with impactful biomedical research and collaborative scientific advancement.[2]

Keywords

Immunotherapy, translational medicine, oncology research, biomedical innovation, pharmaceutical sciences, clinical investigation, scientific impact, therapeutic development.

Introduction

Modern biomedical research increasingly depends on interdisciplinary approaches that integrate molecular biology, immunology, and clinical sciences. Researchers working in these domains contribute to the development of therapeutic strategies designed to address complex diseases. Mohamed Husseiny Elsayed has participated in this evolving scientific landscape through research efforts focused on immunotherapeutic applications and translational outcomes.[3]

Research Profile

The researcher is affiliated with the Beckman Research Institute of City of Hope in the United States. Bibliometric indicators report 65 indexed documents, more than 6,300 citations, and an h-index of 28. These metrics suggest sustained scholarly engagement and measurable visibility within the scientific community, particularly in immunotherapy-related disciplines.[1]

Research Contributions

Research contributions attributed to Mohamed Husseiny Elsayed include studies exploring immune responses, cancer therapeutics, and translational research methodologies. His collaborative publications have supported scientific understanding of treatment optimization and biological mechanisms relevant to disease management. Such work aligns with contemporary priorities in precision medicine and advanced therapeutic development.[4]

Publications

The publication record of Mohamed Husseiny Elsayed includes 65 scholarly documents in immunotherapy and translational oncology, reflecting sustained research productivity, scientific collaboration, and contributions to advancing biomedical knowledge and therapeutic innovation.[4]

Research Impact

Citation activity represents one indicator of scientific influence and knowledge dissemination. With thousands of citations recorded across indexed publications, the researcher demonstrates meaningful engagement from the academic community. The observed citation profile suggests that published findings have contributed to ongoing discussions and developments within biomedical research fields.[3]

Award Suitability

Evaluation for the Innovative Research Award considers originality, scholarly productivity, scientific influence, and relevance to advancing healthcare knowledge. Based on available academic indicators, Mohamed Husseiny Elsayed demonstrates characteristics commonly associated with recognized research excellence. His publication record, citation performance, and institutional affiliation collectively support consideration within competitive academic recognition programs.[2]

Conclusion

The academic profile presented in this article highlights measurable research activity and scholarly engagement within the field of immunotherapy. Bibliometric indicators, institutional affiliation, and documented scientific contributions collectively illustrate an established research trajectory. These characteristics provide a foundation for recognition within academic and professional award frameworks dedicated to scientific innovation.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Mohamed Husseiny Elsayed, Author ID 8580986700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=8580986700
  2. ORCID. (n.d.). Researcher Profile: Mohamed Husseiny Elsayed.
    https://orcid.org/0000-0002-3470-2858
  3. Cobb, J., Rawson, J., Gonzalez, N., Kandeel, F., & Husseiny, M. I. (n.d.). Oral tolerogenic vaccine combined with gastrin restores immune tolerance and beta-cell function in NOD mice with type 1 diabetes.
    https://pubmed.ncbi.nlm.nih.gov/41635853/
  4. Singer, M., Hamdy, R., Ghonaim, J.H., & Husseiny, M.I. Metabolic Imbalance in Immune Cells in Relation to Metabolic Disorders, Cancer, and Infections.
    https://link.springer.com/chapter/10.1007/978-981-96-1305-2_9

Angela Sardaro | Immunotherapy | Excellence in Research

Angela Sardaro | Immunotherapy | Excellence in Research

Assoc. Prof. Dr. Angela Sardaro at ASL Lecce, Italy.

Assoc. Prof. Dr. Angela Sardaro is a distinguished Italian academic and medical professional specializing in Radiotherapy and Diagnostic Imaging. She has served as a professor at the University of Bari Aldo Moro, coordinating degree programs and teaching across multiple disciplines, including Radiology, Oncology, and Medical Imaging. With over 15 years of academic experience, she has guided numerous theses and led scientific seminars. Dr. Sardaro’s prolific research output includes 81 indexed publications, an h-index of 15, and 842 citations ๐Ÿ“ˆ. Her contributions extend globally, with collaborations in the UK and Italy, reinforcing her impact in oncology and radiological science.

Publication Profileย 

scopus

Education

Assoc. Prof. Dr. Angela Sardaro has demonstrated outstanding commitment to medical education ๐Ÿ‘ฉโ€โš•๏ธ๐Ÿ“š, coordinating the Degree Course in Radiologic Imaging and Radiotherapy Techniques at the University of Bari Aldo Moro ๐ŸŽ“. With over 15 years of teaching experience across various undergraduate and postgraduate programs, she has taught core disciplines like Radiotherapy, Radiobiology, and Diagnostic Imaging ๐Ÿงฌ๐Ÿ”ฌ. Her academic service spans doctoral programs, masterโ€™s training in pain therapy, and prestigious collaborations with institutions in Florence and the UK ๐Ÿ‡ฎ๐Ÿ‡น๐Ÿ‡ฌ๐Ÿ‡ง. Dr. Sardaro has delivered 1,440 hours of lectures and 4,160 hours of professional training ๐Ÿ“Š, shaping future generations in radiological sciences.

Experience

Assoc. Prof. Dr. Angela Sardaro has made a remarkable impact on clinical education and hands-on training in radiological sciences ๐Ÿ‘ฉโ€โš•๏ธ๐Ÿงฒ. She has guided radiologic technologists, medical students, and postgraduates through innovative programs that incorporate cutting-edge technologies like PET/CT, proton therapy, and radiogenomics ๐Ÿ’ก๐Ÿงฌ. Her dedication to advancing clinical competence is evident in the numerous experimental and clinical theses completed under her mentorship ๐Ÿ“–๐ŸŽ“. By blending theory with real-world application, she has nurtured a generation of professionals equipped to meet the evolving challenges of diagnostic imaging and radiation therapy.

Research Focusย 

Assoc. Prof. Dr. Angela Sardaroโ€™s research focus lies at the intersection of oncologic radiotherapy, advanced diagnostic imaging, and radiation-induced toxicities ๐ŸŽฏ๐Ÿงฒ. Her work spans critical areas such as hypofractionated radiotherapy, prostate cancer, head and neck squamous cell carcinoma, breast cancer survivorship, and radiogenomics ๐Ÿ“Š๐Ÿงฌ. She also investigates rare radiation-associated tumors like angiosarcomas, while leveraging cutting-edge tools like 18F-FCH PET/CT, MR imaging, and stereotactic radiosurgery ๐Ÿง ๐Ÿ”ฌ. Her systematic reviews and meta-analyses contribute to refining treatment protocols and improving patient outcomes ๐Ÿฉป๐Ÿ‘ฉโ€โš•๏ธ. Dr. Sardaroโ€™s impactful research bridges clinical innovation with evidence-based radiation oncology.

Publication Top Notes

  • Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
  • Nodal assessment and extranodal extension in head and neck squamous cell cancer: insights from computed tomography and magnetic resonance imaging
  • Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments
  • Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity
  • Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease
  • Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis
  • Role of 18F-FCH PET/CT in Detecting Recurrences of Prostate Cancer After Curative Treatments

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Assist. Prof. Dr. Konstantinos Tsapakidis, University Hospital Of Larissa, Greece

Assist. Prof. Dr. Konstantinos Tsapakidis ๐ŸŽ“๐Ÿ‘จโ€โš•๏ธ is an esteemed Medical Oncologist at the University of Thessaly, Greece. With a Ph.D. focused on prostate cancer research, he holds European Certification in Medical Oncology ๐Ÿ…. Since 2018, he has been actively involved in clinical oncology, teaching postgraduate courses on cancer, diet, and immunotherapy ๐Ÿฝ๏ธ๐Ÿงฌ. Dr. Tsapakidis has authored numerous impactful publications ๐Ÿ“š, contributing significantly to cancer diagnostics and treatment. Passionate about education, he trains residents and nurses, advancing oncology knowledge. His expertise includes systemic antineoplastic therapies and immune-oncology ๐ŸŒŸ.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Konstantinos Tsapakidis ๐ŸŽ“ is a dedicated Medical Oncologist with an impressive educational background. He earned his Biology degree from Aristotelian University of Thessaloniki ๐Ÿงฌ (1998โ€“2002) and completed his Medicine degree at the University of Thessaly ๐Ÿฅ (2003โ€“2007). Dr. Tsapakidis achieved his Ph.D. with excellence (2005โ€“2012), researching prostate cancerโ€™s cell-cycle and apoptosis mechanisms ๐Ÿ”ฌ. He specialized in Medical Oncology in 2017 ๐ŸŽฏ and obtained the prestigious European Certification in Medical Oncology in 2018 ๐Ÿ…. He also enhanced his expertise through an Immune-Oncology e-learning program at the University of Piraeus in 2017โ€“2018 ๐Ÿ’ป.

Experience

Assist. Prof. Dr. Konstantinos Tsapakidis ๐Ÿ’ผ has extensive medical oncology experience. Since February 2025, he serves as Assistant Professor at the University of Thessaly ๐ŸŽ“. From 2018 to 2025, he worked as Consultant in Medical Oncology at University Hospital of Larissa ๐Ÿฅ. Previously, he was a University Scholar and Fellow Consultant there (2017โ€“2018) ๐Ÿ‘จโ€โš•๏ธ. He completed his residency in Medical Oncology (2014โ€“2017) and earlier trained in Internal Medicine and Hematology at Larissa hospitals ๐Ÿฉบ. Between 2008โ€“2009, he was a Scientific Associate in Medical Oncology, laying a strong foundation for his clinical career ๐Ÿ”ฌ.

Research Focus

Assist. Prof. Dr. Konstantinos Tsapakidisโ€™s research focus lies primarily in Medical Oncology with a strong emphasis on cancer diagnosis, treatment, and immunotherapy. ๐Ÿงฌ๐Ÿฉบ His work explores various cancer types including lung cancer, breast cancer, sarcomas, and rare cancers, investigating immunotherapy responses, molecular diagnostics, and tumor behavior. ๐Ÿ”ฌ๐Ÿ’‰ He is particularly involved in studying biomarkers like PD-1/PD-L1, immune cell profiling, and novel therapeutic approaches to improve patient outcomes. ๐Ÿงชโš•๏ธ His research also covers cancer-associated complications like thrombosis and metastatic disease. Overall, his contributions advance personalized oncology care and innovative cancer treatment strategies.

Publication Top Notes

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers

Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients

ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Combinatorial analysis of CD4<SUP>+</SUP>Tregs and CD8<SUP>+</SUP>Teff to predict response to ICI in patients with ES-SCLC

Metachronous Single Pulmonary Metastasis of Prostate Cancer: Report of a Rare Case and Literature Review

SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE

A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma COMMENT

Metastatic rectal cancer in the ampulla of Vater: A unique case

Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden